Renin-Angiotensin-Aldosterone System Inhibitors Worsen Anemia in Sickle Cell Disease: Clinical and Mechanistic Insights
Highlight
– Renin-angiotensin-aldosterone system inhibitors (RAASi) are commonly used to manage albuminuria in sickle cell disease (SCD) but may worsen anemia.
– Cross-sectional and longitudinal human studies associate RAASi use with reduced hemoglobin levels independent of other therapies.
– Experimental SCD mouse models demonstrate anemia exacerbation linked to impaired bone marrow erythropoiesis under RAASi treatment.
– Hemoglobin concentration should be closely monitored in patients with SCD receiving RAAS inhibitors to balance kidney benefits with anemia risk.
Study Background
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.